Uncover insights that shape the future of cell and gene therapy manufacturing. Explore expert perspectives, innovative technology experiences , and practical knowledge from Miltenyi Bioindustry as we support the progress of cell and gene therapy from translation to commercial success.
CGT is under pressure from tightened funding, stricter regulations, and persistent scalability challenges, raising the stakes for innovators and COMOs alike. In this interview, Thekla Kurz discusses why proven technology is critical, how supply chain independence creates advantages for customers, and why choosing the right CDMO partner separates accelerated success from costly delays.
Read the full interview
The cell therapy CDMO market is more crowded than ever, but more options don't necessarily make the choice of finding your right partner easier. Here's how to cut through the noise, ask the right questions, and find a partner built for the long haul.
Read the full blog article
